Companies / Israel
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Market remains Buoyant
March 2007 | BMI ViewSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Israel is the most advanced pharmaceuticals sector in the Middle East, boasting one of the highest per capita spends in the region. The market, despite the limited population numbers, will remain buoyant throughout most of the forecast sector, driven by considerable disposable income, demand for latest medicines, epidemiological trends and the activities of the local industry. On the negative side, government cost-containment measures and intellectual property (IP) shortcomings will continue to have a negative impact on the overall figures, despite benefiting generics.